Get the Stockscreener App
55.45
16.57%
7.88
Pre-market:
52.75
-2.70
-4.87%
Qiagen Nv stock is traded at $55.45, with a volume of 15.02M.
It is up +16.57% in the last 24 hours and up +21.65% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$47.57
Open:
$46.2
24h Volume:
15.02M
Relative Volume:
10.42
Market Cap:
$11.42B
Revenue:
$2.04B
Net Income/Loss:
$373.39M
P/E Ratio:
32.69
EPS:
1.6961
Net Cash Flow:
$495.96M
1W Performance:
+17.48%
1M Performance:
+21.65%
6M Performance:
+14.66%
1Y Performance:
+17.20%
1-Day Range:
$46.07
$57.81
1-Week Range:
$46.07
$57.81
52-Week Range:
$37.74
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
55.45 | 9.80B | 2.04B | 373.39M | 495.96M | 1.6961 |
|
TMO
Thermo Fisher Scientific Inc
|
619.01 | 232.46B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
234.33 | 166.69B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
686.02 | 57.12B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
233.69 | 40.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.83 | 39.59B | 6.95B | 1.30B | 1.15B | 4.5696 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
QIAGEN NV : Buy rating from Jefferies - marketscreener.com
Middle East Exosomes Market Research Report 2025-2033: Diagnostic and Therapeutic Adoption, R&D Investment, and Liquid Biopsy Demand Drive Growth - GlobeNewswire Inc.
Qiagen Said to Weigh Strategic Options Amid Fresh Interest - Bloomberg
Qiagen (QGEN) Hits 4-Year High as Earnings Loom - Insider Monkey
Qiagen (NYSE:QGEN) Sets New 52-Week HighStill a Buy? - MarketBeat
Qiagen (QGEN) Shares Surge Amid Takeover Speculation - GuruFocus
Agilent and Danaher Eye Qiagen Acquisition as Shares Surge 19% - Intellectia AI
Agilent, Danaher could be potential buyers of Qiagenanalyst (QGEN:NYSE) - Seeking Alpha
Qiagen stock price jumps nearly 16% as Bloomberg report revives sale talk - TechStock²
Qiagen gains on report it's weighing options amid takeover interest - MSN
Dutch biotech company soars: Rumors of discussions with potential buyers - medwatch.com
Qiagen (QGEN) Surges 12% Amid Potential Sale Discussions - GuruFocus
Qiagen (QGEN) Evaluates Sale Options Amid Takeover Interest, Shares Up 12% - Intellectia AI
Qiagen weighing strategic options amid fresh takeover interest, Bloomberg reports - Reuters
QIAGEN Stock Poised for Movement Amid Q4 Results Announcement - StocksToTrade
QGEN Stock Rises Amid Potential Sale Discussions - GuruFocus
Qiagen stock soars after report company weighing strategic options By Investing.com - Investing.com Nigeria
Qiagen stock soars after report company weighing strategic options - Investing.com
Qiagen Is Said to Consider Strategic Options Amid Fresh Interest - Bloomberg.com
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast - sharewise.com
How to listen to QIAGEN’s Q4 2025 earnings webcast on Feb. 5 - Stock Titan
23,093 Shares in Qiagen N.V. $QGEN Purchased by SG Americas Securities LLC - MarketBeat
Qiagen N.V. $QGEN Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Sumitomo Mitsui Trust Group Inc. Invests $7.29 Million in Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. (NYSE:QGEN) Short Interest Down 20.2% in December - MarketBeat
Campbell & CO Investment Adviser LLC Makes New Investment in Qiagen N.V. $QGEN - MarketBeat
Analysis Recap: Is Qiagen NV stock a smart retirement pickJuly 2025 Earnings & Safe Capital Investment Plans - baoquankhu1.vn
Qiagen Reports AFM Notification of Major Stake by Massachusetts Financial Services - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView — Track All Markets
Release according to Article 40, Section 1 of the WpHG - TradingView — Track All Markets
QIAGEN NV : Receives a Buy rating from DZ Bank - marketscreener.com
Qiagen N.V.: How a Quiet Diagnostics Powerhouse Became a Platform Bet on the Future of Medicine - AD HOC NEWS
Qiagen and Gencurix partner for oncology tests - MSN
Did Qiagen’s (QGEN) AI and Automation Push Just Redefine Its Diagnostics Investment Narrative? - simplywall.st
JPM26: Qiagen outlines key priorities to drive momentum in 2026 - Medical Device Network
Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co., QIAGEN and More - GlobeNewswire
Aug Momentum: How Qiagen NV stock performs in interest rate cycles2025 Big Picture & High Accuracy Swing Entry Alerts - Bộ Nội Vụ
QIAGEN Board Member’s Holdings Adjusted Following Share Consolidation - TipRanks
QIAGEN Adjusts Management Shareholdings Following Synthetic Share Repurchase - TipRanks
QIAGEN Adjusts Board Member Shareholding Following Synthetic Share Consolidation - TipRanks
QIAGEN discloses management share consolidation under synthetic repurchase program - TipRanks
QIAGEN adjusts insider shareholdings after synthetic share repurchase and consolidation - TipRanks
QIAGEN adjusts board member shareholding after synthetic share consolidation - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView — Track All Markets
Qiagen N.V.: Diagnostics Specialist Tests Investor Patience Amid Sideways Trading and Selective Opti - AD HOC NEWS
Qiagen (QGEN) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth - BioSpace
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Soli - PharmiWeb.com
Qiagen sets 2026 priorities to drive growth - marketscreener.com
Qiagen N.V.: How a Quiet Diagnostics Powerhouse Became a Genomics Infrastructure Play - AD HOC NEWS
Published on: 2026-01-10 23:18:15 - ulpravda.ru
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.90%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):